NASDAQ
ATXI

Avenue Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Avenue Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.76
Today's High:
$0.819
Open Price:
$0.76
52W Low:
$0.874
52W High:
$16.65
Prev. Close:
$0.72
Volume:
107923

Company Statistics

Market Cap.:
$8.87 million
Book Value:
-0.213
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-139.49%
Return on Equity TTM:
-107.28%

Company Profile

Avenue Therapeutics Inc had its IPO on 2017-06-27 under the ticker symbol ATXI.

The company operates in the Healthcare sector and Biotechnology industry. Avenue Therapeutics Inc has a staff strength of 2 employees.

Stock update

Shares of Avenue Therapeutics Inc opened at $0.76 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.76 - $0.82, and closed at $0.79.

This is a +10.35% increase from the previous day's closing price.

A total volume of 107,923 shares were traded at the close of the day’s session.

In the last one week, shares of Avenue Therapeutics Inc have increased by +0.7%.

Avenue Therapeutics Inc's Key Ratios

Avenue Therapeutics Inc has a market cap of $8.87 million, indicating a price to book ratio of 14.288 and a price to sales ratio of 0.

In the last 12-months Avenue Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Avenue Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Avenue Therapeutics Inc’s operating margin was 0% while its return on assets stood at -139.49% with a return of equity of -107.28%.

In Q1, Avenue Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Avenue Therapeutics Inc’s PE and PEG Ratio

Forward PE
17.9856
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-2.98 per share while it has a forward price to earnings multiple of 17.9856 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avenue Therapeutics Inc’s profitability.

Avenue Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.198. Its price to sales ratio in the trailing 12-months stood at 0.

Avenue Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$8.45 million
Total Liabilities
$10.60 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Avenue Therapeutics Inc ended 2024 with $8.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.45 million while shareholder equity stood at $-1452000.00.

Avenue Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.60 million in other current liabilities, 1000.00 in common stock, $-88087000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.24 million and cash and short-term investments were $8.24 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Avenue Therapeutics Inc’s total current assets stands at $8.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13000.00 compared to accounts payable of $1.84 million and inventory worth $0.

In 2024, Avenue Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Avenue Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.79
52-Week High
$16.65
52-Week Low
$0.874
Analyst Target Price
$32

Avenue Therapeutics Inc stock is currently trading at $0.79 per share. It touched a 52-week high of $16.65 and a 52-week low of $16.65. Analysts tracking the stock have a 12-month average target price of $32.

Its 50-day moving average was $1 and 200-day moving average was $1.15 The short ratio stood at 0.58 indicating a short percent outstanding of 0%.

Around 1569.5% of the company’s stock are held by insiders while 1194.2% are held by institutions.

Frequently Asked Questions About Avenue Therapeutics Inc

The stock symbol (also called stock or share ticker) of Avenue Therapeutics Inc is ATXI

The IPO of Avenue Therapeutics Inc took place on 2017-06-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.05
-0
-6.83%
$49.22
-3.84
-7.24%
$2.37
-0.31
-11.57%
$73.95
-3.89
-5%
$4.73
-0.18
-3.67%
$804.15
-29.05
-3.49%
$27.03
-0.1
-0.37%
$108.2
-4.1
-3.65%
$59.29
-0.34
-0.57%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Address

1140 Avenue of the America, New York, NY, United States, 10036